© Drug Hunter Inc. 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > AG-881
<< Back to February
allosteric mutant IDH1/2 dual inhibitor
oral, brain penetrant, completed Ph. I in HV
from SBDD of prior mIDH inhibitor
ACS Med. Chem. Lett., 2020, 11, 101-107
Agios Pharmaceuticals, Cambridge, MA
AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)
Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.